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Abstract
Background: The aim of this study is to validate a previously published consensus-based quality indicator set for
the management of patients with traumatic brain injury (TBI) at intensive care units (ICUs) in Europe and to study
its potential for quality measurement and improvement.
Methods: Our analysis was based on 2006 adult patients admitted to 54 ICUs between 2014 and 2018, enrolled in
the CENTER-TBI study. Indicator scores were calculated as percentage adherence for structure and process indicators
and as event rates or median scores for outcome indicators. Feasibility was quantified by the completeness of the
variables. Discriminability was determined by the between-centre variation, estimated with a random effect regression
model adjusted for case-mix severity and quantified by the median odds ratio (MOR). Statistical uncertainty of outcome
indicators was determined by the median number of events per centre, using a cut-off of 10.
Results: A total of 26/42 indicators could be calculated from the CENTER-TBI database. Most quality indicators proved
feasible to obtain with more than 70% completeness. Sub-optimal adherence was found for most quality indicators,
ranging from 26 to 93% and 20 to 99% for structure and process indicators. Significant (p < 0.001) between-centre
variation was found in seven process and five outcome indicators with MORs ranging from 1.51 to 4.14. Statistical
uncertainty of outcome indicators was generally high; five out of seven had less than 10 events per centre.
Conclusions: Overall, nine structures, five processes, but none of the outcome indicators showed potential for quality
improvement purposes for TBI patients in the ICU. Future research should focus on implementation efforts and
continuous reevaluation of quality indicators.
Trial registration: The core study was registered with ClinicalTrials.gov, number NCT02210221, registered on August
06, 2014, with Resource Identification Portal (RRID: SCR_015582).
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Background
Limited evidence is available to direct critical care prac-
tice in patients with traumatic brain injury (TBI) [1].
Randomized controlled trials have shown a limited po-
tential to add evidence translatable to clinical practice,
and new approaches are being explored to improve care,
such as quality of care monitoring. Quality of care
registration in patients with TBI could become part of
an emerging international intensive care unit (ICU) or
trauma registries [2–5]. When used over time and across
centres, large datasets provide a rich source for bench-
marking and quality improvement, i.e. with feedback on
performance, between-centre discussions on policies,
and opportunities to study best practice.
International registries can contribute to improved pa-
tient outcome, by identifying areas in need of quality im-
provement, informing health policies, and increasing
transparency and accountability, as shown in other
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medical fields, like cancer [6], acute coronary syndrome
[7], and cystic fibrosis [8]. Benchmarking TBI manage-
ment between ICUs can only be reliable when standard-
ized quality indicators are used and case-mix correction
is applied [5]. Quality indicators can be subdivided into
structure, process, and outcome indicators [9]. As no
quality indicator set is available for patients with TBI, we
recently performed a Delphi study to reach consensus
on a quality indicator set [10].
The aim of the current study is to validate the
consensus-based quality indicator set. We hereto ana-
lyzed patients enrolled in a large dataset of patients with
TBI from the Collaborative European NeuroTrauma Ef-
fectiveness Research in Traumatic Brain Injury (CEN-
TER-TBI) study. Data collected for CENTER-TBI
included a comprehensive description of ICU facilities
and patient outcomes in 54 centres, thus providing an
opportunity to examine the usefulness of the newly de-
veloped indicator set [11]. Based on the validation result,
the indicator set could be reduced to those that have the
greatest potential for implementation.
Methods
Quality indicator set
In this validation study, we applied a previously developed
quality indicator set based on a Delphi study to the
CENTER-TBI study. The quality indicator set consisted of
17 structure, 16 process, and 9 outcome indicators for adult
patients with TBI at the ICU. It was acknowledged that this
initial set would be in need of further validation [10].
Data
The CENTER-TBI study is a multicentre observa-
tional cohort study conducted in Europe, which re-
cruited patients between 2014 and 2018 (Clinicaltrials.
gov NCT02210221) [11, 12]. The core study contains
4509 patients. Inclusion criteria for the CENTER-TBI
study were a clinical diagnosis of TBI, presentation
within 24 h of injury, an indication for CT scanning,
and the exclusion criterion was a pre-existing (severe)
neurological disorder that could confound outcome
assessments. We selected ICU patients for this study
as the consensus-based indicators were specifically de-
veloped for the ICU. So, the inclusion criteria for our
study were (1) admitted to the ICU and (2) adults
older than 18 years. Processes of ICU care (vitals,
treatments, and therapy intensity levels) were obtained
on a daily basis. Outcomes were assessed at the ICU
and at 3, 6, 12, and 24 months. In addition, question-
naires were completed by participating centres on
structures and processes of care (Provider Profiling
questionnaires [13]).
Indicator scores
We determined whether the indicators could be calcu-
lated from the CENTER-TBI database and whether data
collection fitted routine practice.
Structure indicator scores at centre level were calcu-
lated based on the Provider Profiling questionnaires and
expressed as the number of centres that indicated that
the structure was either present or absent.
Process indicators were calculated as the number of
patients adherent to the indicator (numerator) divided
by the number of patients to which the indicator could
have applied per centre (denominator). The denomin-
ator could be based on a subset of patients (e.g. exclud-
ing patients with leg fractures for the indicator
mechanical DVT prophylaxis).
(Crude) outcome indicators were calculated as the event
rate of the indicator per centre (numerator) divided by the
total number of patients which could have scored on the in-
dicator (denominator). For the Glasgow Outcome Scale Ex-
tended (GOSE) and Short Form-36 version 2 (SF-36), the
median scores were calculated.
Missing data were disregarded for the denominator so
that the indicator adherence scores were based on the
number of patients that could be exposed to the indica-
tor. We present the median indicator numbers across
centres with interquartile range.
Validation of the quality indicators
The usefulness of the quality indicators was based on
three criteria [14]: feasibility [15], discriminability [16, 17],
and statistical uncertainty [15, 18, 19]. As no previous
studies report thresholds on these criteria, we set a priori
thresholds based on consensus.
Feasibility
Feasibility addresses data quality and ease of quality indi-
cator calculation [15].
The feasibility was quantified by the completeness of
the variables required to calculate the indicators. We set
an arbitrary threshold of > 70% completeness of data (of
denominator) to determine feasibility.
Discriminability
To determine discriminability (between-centre vari-
ation), we determined the between-centre differences in
adherence to quality indicators to evaluate their poten-
tial for benchmarking and quality improvement [16, 17].
Between-centre variation for structure indicators was
determined by the number of centres having that struc-
ture. We set an arbitrary threshold for moderate dis-
criminability at 80–90% and for poor discriminability at
90–100% adherence to structure and process indicators.
Such high levels of adherence decrease discrimination
between centres.
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The between-centre variation of process and outcome
indicator scores, adjusted for case-mix and statistical un-
certainty, was quantified with the median odds ratio
(MOR) [20]. The MOR represents the odds of being ad-
herent to a specific indicator for two patients with the
same patient characteristics from two randomly selected
centres. The higher the MOR, the larger the between-
centre variation (a MOR equal to 1 reflects no variation).
For process and outcome indicators, we considered a
low (unadjusted) interquartile range on scores (IQR <
10) or non-significant (adjusted) between-centre differ-
ences or a MOR of 1.1 or less as poor discriminability.
Case-mix- and uncertainty-adjusted process and out-
come indicator scores per centre were presented in cat-
erpillar plots.
Statistical uncertainty
Reliability refers to the reproducibility of a quality indica-
tor and is threatened by unclear indicator definitions [15]
and statistical uncertainty [18, 19]. We determined
whether we could calculate indicators in a uniform way or
made minor changes to definitions. Statistical uncertainty
was determined by random variation due to low numbers
of events (only applicable to outcome indicators).
Statistical uncertainty for outcome indicators was de-
termined by the median number of events across cen-
tres. We set the threshold for high statistical uncertainty
at < 10 events.
Statistical analysis
Baseline centre and patient characteristics are described
as frequencies and percentages. Between-centre variation
of process and outcome indicator scores was calculated
with a random-effect logistic regression analysis. We
used a random effect model (random effect for centre)
to account for the fact that indicator scores in centres
with a small number of patients can have extreme values
due to random variation. Also, only centres with > 10
admitted ICU patients were included. To correct for
case-mix, we used the extended International Mission
for Prognosis and analysis of Clinical Trials in TBI (IM-
PACT) prognostic model: core (age, motor score,
pupillary light reactivity), CT (hypoxia, hypotension, epi-
dural hematoma, traumatic subarachnoid hemorrhage,
and Marshall CT classification) and lab (first glucose
and hemoglobin) [21], and injury severity score (ISS).
The MOR was calculated from the τ2 (variance of ran-
dom effects).
Case-mix- and uncertainty-adjusted process and out-
come indicator scores per centre are presented in ‘cater-
pillar’ plots. p values for determining the significance of
the between-centre variation were calculated with a like-
lihood ratio test comparing a model with and without a
random effect for centre. A mixture distribution is
required to calculate the p value as the null hypothesis is
on the boundary of the parameter space [22].
For the calculation of random effect models, missing
data were imputed with multiple (N = 5) imputation with
the MICE package from R [23]. Statistical analyses were
performed in R statistical software. Neurobot version 2.1
(data extraction date 23-12-2019) was used.
Results
A total of 26 (11 structure, 8 process, and 7 outcome indi-
cators) of the 42 indicators of the Delphi set could be ex-
tracted from the CENTER-TBI database. (Additional file 1).
Baseline data
Fifty-four centres from 18 countries were included, total-
ing 2006 adult patients. The median number of ICU pa-
tients included per centre was 23 (IQR12–43, range 2–
119). Centres were mostly academic centres (N = 51;
94%) and designated as level I trauma centres (N = 37;
69%). Most centres were located in Northern (N = 20;
37%) or Western Europe (N = 19; 35%) (Table 1).
Around 28% of patients admitted to ICU were older
than 65 years and mostly male (N = 1561; 73%). Accord-
ing to the baseline GCS score, 48% had severe (GCS < 9;
N = 915), 16% moderate (GCS 9–12; N = 305), and 48%
mild TBI (GCS 13–15; N = 671). The majority of patients
(N= 1963; 96%) suffered from polytrauma. The cause of
injury was mostly related to road traffic accidents (N =
849; 44%) or incidental falls (N = 802; 42%) (Table 1).
Adherence
Regarding structure indicators, sub-optimal adherence
rates were found for most indicators, including the pres-
ence of a neuro-ICU (N = 35; 65%), operation room
availability 24 h per day (N = 40; 75%), and presence of a
step-down unit (N = 38; 70%) (Additional file 2). Patient-
to-nurse ratio’s varied, with reported ratios of 1 (N = 14;
26%), 1–2 (N = 23; 43%), and 2–3 (N = 17; 31%) patients
per nurse. Adherence was high for ‘the existence of a
protocol including specific guidelines’ (N = 47; 89%),
‘protocol for glucose management’ (N = 43; 81%), ‘the
availability of a neurosurgeon within 30 minutes after
call’ (N = 49; 93%), and ‘the 24/7 availability of a CT scan
and radiologist review’ (N = 50; 91%).
Sub-optimal adherence rates were found for most
process indicators, including ICP monitoring in the severe
TBI group (median 69%, IQR 44–82), basal caloric intake
within 5–7 days (N = 20%, IQR 3–47), and ‘patients that
receive DVT prophylaxis with low molecular weight hepa-
rins’ (median 63%, IQR 49–78) (Additional file 3). Adher-
ence was high for ‘enteral nutrition within 72 hours’
(median 99%, IQR 87–100).
For outcome, the centres had a median [IQR] ICU
mortality of 12% [9–21], ventilator-acquired pneumonia
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Table 1 Baseline centre and patient characteristics
Centre characteristics Centre level (N = 54) Patient level (N = 2006)
N % N %
Centre
Academic 51/54 94 1901/2006 95
Nonacademic 3/54 6 105/2006 5
Centre locationa
Urban 53/54 98 1990/2006 99
Suburban 1/54 2 16/2006 1
Trauma designationb
Level I 37/54 69 1468/2006 73
Level II 4/54 7 84/2006 4
Level III 1/54 2 135/2006 7
No designation/NA 12/54 22 319/2006 16
Electronic patient records at the ICU
Yes 42/54 78 1690/2006 84
No 12/54 22 316/2006 16
Locationc
Northern Europe 20/54 37 650/2006 33
Western Europe 19/54 35 809/2006 40
Southern Europe 12/54 22 524/2006 26
Eastern Europe 2/54 4 22/2006 1
Israel 1/54 2 1/2006 0
Patient characteristics Centre level (N = 54) Patient level (N = 2006)
Median % IQR Min-max N %
Age (years)d
Adults (≥ 18 < 65 years) 74 63–84 0–100 1454/2006 72
Elderly (≥ 65 years) 26 16–37 0–100 552/2006 28
Gender
Male 76 67–83 55–100 1479/2006 74
Female 25 19–33 6–46 527/2006 26
TBI severity (GCS)e
Mild 13–15 34 22–43 5–100 671/1891 35
Moderate 9–12 17 11–21 4–38 305/1891 16
Severe 3–8 53 40–61 18–100 915/1891 48
ISS score
< 16 7 3–14 1–24 76/1963 4
≥ 16 100 96–100 76–100 1887/1963 96
AISf
Thorax/chest ≥ 3 33 20–40 8–100 654/2006 33
Abdomen/pelvis ≥ 3 9 6–13 1–33 173/2006 9
Cause of injury
Road traffic incident 45 35–55 0–68 849/1921 44
Incidental fall 40 33–50 11–100 802/1921 42
Violence/assault 2 0–7 0–43 83/1921 5
Suicide attempt 0 0–3 0–20 44/1921 2
Other 6 0–11 0–38 143/1921 7
This table describes the centre characteristics (at centre level) and the entire ICU population (patient level)
AIS Abbreviated Injury Scale, GCS Glasgow Coma Scale, ICU intensive care unit, ISS injury severity scale, NA not applicable, TBI traumatic brain injury
aUrban: A hospital location very near to a city and situated in a crowded area. Suburban: between urban and rural (an hospital location in or very near to the
countryside in an area that is not crowded)
bLocation is based on United Nations geoscheme: Northern Europe = Norway (N = 163), Sweden (N = 87), Finland (N = 132), Denmark (N = 3), the UK and Ireland
(N = 271), and Baltic States: Latvia (N = 10), Lithuana (N = 23); Western Europe = Austria (N = 109), Belgium (N = 193), France (N = 115), Germany (N = 87), and the
Netherlands (N = 359); Southern Europe = Serbia (N = 10), Italy (N = 293), and Spain (N = 195); Eastern Europe = Romania (N = 3), Hungary (N = 20);
cLevel I trauma centre: A regional resource centre that generally serves large cities or population-dense areas. A level I trauma centre is expected to manage large
numbers of severely injured patients (at least 1200 trauma patients annually or have 240 admissions with an injury severity score of more than 14). It is
characterized by a 24-h in-house availability of an attending surgeon and the prompt availability of other specialties (e.g. neurosurgeon, trauma surgeon). Level II
trauma centre: A level II trauma centre provides comprehensive trauma care in either a population-dense area in which a level II trauma centre may supplement
the clinical activity and expertise of a level I institution or occur in less population-dense areas. In the latter case, the level II trauma centre serves as the lead
trauma facility for a geographic area when a level I institution is not geographically close enough to do so. It is characterized by a 24-h in-house availability of an
attending surgeon and the prompt availability of other specialties (e.g. neurosurgeon, trauma surgeon). Level III trauma centre: A level III trauma centre has the
capacity to initially manage the majority of injured patients and have transfer agreements with a level I or II trauma centre for seriously injured patients whose
needs exceed the facility’s resources
dThe number of centres that admitted children was 27; therefore, the distribution and median is skewed towards 1%. One centre included 1 patient that was an
elderly person (therefore max = 100%)
eGCS at baseline: Post stabilization value, if absent prehospital values are used. Intubated/untestable verbal (V) scores are treated as unknown
fAIS score of 3 or more reflects serious extracranial injury
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(VAP) incidence of 14% [0–31], and hyperglycemia inci-
dence of 35% [22–45]. The median [IQR] GOSE was 5
[3–7], the SF-36v2 physical component summary (PCS)
46 [37–54], and SF-36v2 mental component summary
(MCS) was 46 [36–55] (Additional file 4).
Feasibility
Feasibility of structure indicators was generally high
(overall more than 98% available data). Feasibility was
low for one process indicator: ‘mechanical DVT prophy-
laxis within 24 hours’ (43% available data). Feasibility was
high for outcome indicators, except for the SF-36 MCS
and PCS scores (28% available data) collected after 6
months (due to loss to follow-up) (Additional files 2, 3, 4).
Overall, one process and one outcome indicator
showed low feasibility (Table 2).
Discriminability
Variation in scores between centres was low for struc-
ture indicators (with little room for improvement) for
‘existence of a protocol’, ‘availability of a neurosurgeon
24/7 within 30 minutes after call’, and ‘24/7 availability
of a CT scan and radiologist review’, due to high overall
adherence rates among centres (Additional file 2). For
process indicators, high variation was found for all indi-
cators (all MORs above 1.5, all p < 0.001) except for ‘sur-
gery within 4 hours in patients with SDH or EDH’
(Fig. 1).
For outcome indicators, the between-centre variation
was significant as well. The variation between centres
was especially high for ventilator-acquired pneumonia
(VAP) with a MOR of 4.12. Little between-centre vari-
ation on the 6-month GOSE was found (MOR = 1.29,
p = 0.5) (Fig. 2).
Overall, five structure (three with moderate perform-
ance), two process, and four outcome indicators showed
low discriminability (Table 2).
Statistical uncertainty
Four indicator definitions were slightly changed without
changing its content (Additional files 3 and 4, bold defi-
nitions). Median event rates for the outcome indicators
hyperglycemia, ICU mortality, and ventilator-associated
pneumonia (VAP) were respectively 8, 4, and 3 events
per centre. Median event rates for hypoglycemia and de-
cubitus were zero. All these event rates reflect high stat-
istical uncertainty (Additional file 4, Table 2).
Discussion
We showed that it was feasible to obtain most quality in-
dicators from a recently proposed, consensus-based, qual-
ity indicator set for traumatic brain injury (TBI) at the
ICU based on sufficient data completeness. The subopti-
mal adherence scores in combination with between-centre
variation suggest a potential for quality improvement, spe-
cifically for process and outcome indicators. However,
statistical uncertainty was generally high for outcome indi-
cators, making them less suitable for quality improvement
purposes and benchmarking in particular. Based on the
assessment of feasibility, discriminability, and statistical
uncertainty, we found nine structure indicators, five
process indicators, but none of the outcome indicator out
of 26 indicators to be appropriate for quality measurement
and improvement in this validation study. Overall, the
quality of ICU care can be improved for patients with TBI,
and our analysis provides a useful case of how quality indi-
cators for ICU care in TBI can be evaluated in a large
database.
To our knowledge, this is the first quality indicator set
to be developed and validated in adult patients with TBI
admitted to the ICU. We have summarized quality indi-
cators with the potential to be used for benchmarking
and quality improvement. First, we recommend reducing
the initial set by excluding indicators with a low percent-
age available data (low feasibility), in a given dataset.
The low feasibility on some process indicators might be
explained by the complexity and high resource needs of
collecting data on process indicators. However, feasibility
could be improved with automatic data extraction in the
future. Second, quality indicators with high between-
centre variation (most quality indicators in this study)
and suboptimal adherence rates (discriminability) can be
used to improve quality of care and for benchmarking.
Third, event rates of outcome indicators were generally
low (even over a study duration of 4 years), indicating
that outcome indicators have a low potential for quality
improvement in this study population due to high statis-
tical uncertainty. However, the threshold of 10 events
might be too strict, or alternatively, outcome indicator
denominators should be restricted to patients with a
more severe injury, greater organ dysfunction, more in-
terventions, or longer length of stay to increase the
number of events and to increase statistical power. Over
time, registration and use of the quality indicators could
provide further insights into their role in quality im-
provement and benchmarking and allow their re-
evaluation and refinement.
Quality of care in critically ill patients with TBI could
potentially be improved in various areas, as indicated by
a sub-optimal adherence of European ICUs to most
quality indicators. The large (adjusted) between-centre
variation suggests that some centres significantly outper-
form others. Wide sharing of best practice and imple-
mentation strategies from centres that perform well on
quality indicators describing structures and processes of
care and/or registering a low incidence of adverse out-
comes could improve performance in centres that per-
form less well.
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Table 2 Overview of indicator performance
This table gives an overview of the performance of indicators based on the main results of this study. The colors indicate poor (red), moderate (orange), or good
(green) performance on feasibility and discriminability (adherence rates or between-centre variation). The adherence rates and event rates are shown as the
median indicator scores across centres. For the determination of the feasibility, we calculated the amount of available data at patient level
Discriminability is determined by adherence rates and between-centre variation: high adherence rates for structures and processes are considered as low
discriminability. Discriminability is also reflected in the IQR (unadjusted) and the MOR (adjusted for case-mix and random variation). For outcome indicators, the
statistical uncertainty (median number of events) was determined
Feasibility: we determined that > 70% available data reflects good performance
Discriminability: the potential for quality improvement was determined by the percentage adherence of centres to structure and process indicators (i.e. with high
adherence rates, quality of care cannot be improved that much). We set the threshold for moderate potential for quality improvement at 80–90% and for poor
potential at 90–100%. In addition, we considered a low (unadjusted) interquartile range on scores (IQR < 10) or non-significant (adjusted) between-centre
differences as poor performance
BTF Brain Trauma Foundation, DVT deep venous thrombosis, EDH epidural hematoma, GCS Glasgow Coma Scale, ICU intensive care unit, GOSE Glasgow Outcome
Scale Extended, IQR interquartile range, MOR median odds ratio, OR odds Ratio, SDH subdural hematoma, TBI traumatic brain injury
*Statistical uncertainty for outcome indicators (the less complications, the better the quality of care) was determined by the median number of events/median
number of included patients per centre. We set the threshold for poor potential at less than 10 events
aPharmaceutical or mechanical
bBased on the IQR
cBased on non-significant between-centre differences
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Previous studies also report large between-centre dif-
ferences in processes of TBI care across Europe [24–26].
This between-centre variation could be explained by
variation in adherence to guidelines. Although 89% of
centres indicated that they complied with the Brain
Trauma Foundation (BTF) guidelines, actual assessment
of real-time practice may be different. For example, ICP
monitoring in patients with severe TBI (GCS < 9) is one
of the higher-level evidence recommendations in the
BTF guidelines, but we only found adherence rates of
44–82% (IQR) across centres in our study. This implies
that there is much to gain in the reduction of variation
Fig. 1 Adjusted random effect estimates per centre for process indicators. This figure shows the between-centre differences for the process
indicators (beware of different x-axes). Quality indicator definitions can be found in Additional file 3. On the y-axis, each dot represents a centre. A
centre with an average indicator score has log odds 0 (a positive log odds indicates higher indicator scores and a negative log odds lower
indicator scores). The between-centre differences are represented by the shape of the caterpillar plots; the variation in the log odds for individual
centres and the corresponding confidence intervals (uncertainty). For example, the use of ICP monitoring shows large variation between centres
with small confidence intervals, so there is high variation with low statistical uncertainty. While for use of low molecular weight heparin, the
variation is large, but the statistical uncertainty is high as well (due to high adherence rates for most centres). The caterpillars were based on non-
missing data (after imputation). ‘Use of Low Molecular Weight Heparin’ reflects the indicator ‘Number of patients that receive pharmaceutical
prophylaxis with low molecular weight heparins/ total number of TBI patients admitted to the ICU’. ‘Surgery within 4 hours’ reflects the indicator
‘Median door-to-operation time for acute operation of SDH and EDH with surgical indication’. DVT deep venous thrombosis, EDH epidural
hematoma, ICU intensive care unit, MOR median odds ratio, SDH subdural hematoma
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in evidence-based care processes. One previous study re-
ported the performance of quality indicators in children
with TBI [27]. Although their indicators differed from
those in the current study, they found a lower variation
in adherence rates (between 68% and 78%). Several
registries already exist for general ICU [3, 5]—or trauma
care [2, 4]. Some of the outcome indicators we tested
are also used in current ICU registries but did not
perform well in our study (decubitus ulcers and
hypoglycemia). For example, in our study, the outcome
score for decubitus ulcers approached 0%, while in
Dutch hospitals, decubitus was found in around 6% of
patients [16].
This study has several strengths. First, we tested the
potential of consensus-based quality indicators in a large
clinical dataset, while most previous studies only report
Fig. 2 Adjusted random effect estimates per centre for outcome indicators. This figure shows the between-centre differences for the outcome
indicators. Quality indicator definitions can be found in Additional file 4. On the y-axis, each dot represents a centre. A centre with an average
indicator score has log odds 0 (a positive log odds indicates higher indicator scores and a negative log odds a lower indicator scores). Outcome
indicator scores were adjusted for case-mix and ‘statistical uncertainty’ (variation by chance) by using a random effects logistic regression model.
The MOR (median odds ratio) represents the between-centre variation: the higher the MOR, the larger the between-centre variation (a MOR equal
to 1 reflects no variation). The confidence intervals represent the statistical uncertainty. The caterpillars were based on non-missing data (after
imputation). Outcome incidence for decubitus and hypoglycemia was too low to reliably show between-centre variation (high confidence
intervals). Impaired SF-36v2 (PCS or MCS) score≤ 40. CI confidence interval, GOSE Glasgow Outcome Scale Extended, ICU intensive care unit, MOR
median odds ratio
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a Delphi study to develop quality indicators and only a
few studies pilot-tested quality indicators before imple-
mentation [28, 29]. Second, the indicator scores were de-
rived from the CENTER-TBI database, which includes a
substantial number of patients with TBI across many
ICUs. Indeed, this analysis provides the first opportunity
to study indicator performance and between-centre vari-
ation in TBI management on a larger scale. The
CENTER-TBI database has only one exclusion criterion,
so it represents a cohort generalizable to the TBI popu-
lation across Europe.
Our study also has some limitations. Staffing and
organizational data were only partly captured in
CENTER-TBI. The structure indicators were based on
questionnaires which might be imprecise. Patients of all
severities (including early deaths) were included for ana-
lyses. We recognize that a selection of patients with a
longer ICU stay may have increased between-centre
comparability, but we mitigated this issue by correcting
all between-centre analyses for case-mix severity. We de-
fined feasibility as the completeness of the data, while
other aspects of feasibility, such as accessibility, timeli-
ness, and missing data at a centre level, could not be ad-
dressed [30]. Statistical uncertainty was reflected in the
number of event rates, while also other aspects as intra-
and inter rater reliability of medical coders are import-
ant but could not be addressed. We decided not to test
the construct (correlations between indicators) and cri-
terion validity (association with outcome) of the final in-
dicator set as these are hard to test [31]; for construct
validity, predetermined correlations between quality in-
dicators are hard to find between different aspects of
processes of care and often do not correlate with out-
come; and for criterion validity, the case-mix adjustment
would differ per quality indicator and even very complex
models cannot adjust for all residual bias (unmeasured
confounding). However, ongoing evaluation of these
quality indicators in larger datasets could include assess-
ment of such correlations with the outcome.
Future implementation of the quality indicators in a
European registry will make it possible to monitor TBI
patient data over time and among countries. Feedback
from this registry to individual ICUs is essential to make
stakeholders be aware of their centre performance and
help develop internal quality improvement programmes.
No reference standards for the quality indicators have
been defined. Our study also illustrates some pitfalls,
since some of these indicators are quite complex and
difficult to assess retrospectively. Such data collection
could, however, be optimized by routine registration of
timing of events and processes, automatic data extrac-
tion, and clear definitions. Overall, the methods illus-
trated in this study can be used to optimize future data
collection (with uniform indicator definitions and data
quality), to calculate quality indicators (adjusted across
centres) and to identify areas in need of further research
(due to high variation).
Conclusions
This study validated a consensus-base quality indicator
set in a large prospective TBI study (CENTER-TBI).
Quality of care in critically ill patients with TBI appears
amenable to improvement in various areas as indicated
by sub-optimal adherence rates and between-centre vari-
ation for many quality indicators. Further, our analysis
generally shows good feasibility and discriminability but
high statistical uncertainty for several outcome indica-
tors. Future research should focus on implementation
and quality improvement efforts and continuous reevalu-
ation of the quality indicators.
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